Proactive Investors - Run By Investors For Investors

Admedus eyes new revenue stream through supply agreement with 4C Medical Technologies

4C is a developer of minimally invasive therapies for structural heart disease.
Admedus eyes new revenue stream through supply agreement with 4C Medical Technologies
Admedus is a medical technologies company

Admedus Ltd (ASX:AHZ) has entered into an exclusive supply agreement with 4C Medical Technologies, Inc.

Under the agreement, 4C Medical will add the latest innovation in cardiovascular tissue engineering from Admedus to their novel transcatheter mitral regurgitation treatment technology.

Specifically, the functioning valve apparatus of the 4C implant will utilise tissue processed by Admedus’ clinically superior ADAPT® Tissue Engineering Process for the functioning leaflet component.

This additional key technology optimizes function and durability.

Wayne Paterson, chief executive officer for Admedus, said that he is confident the deal will generate a significant new revenue stream.

"4C Medical has already made significant progress on its development path in the very challenging TMVR space.

"We can now explore potential co-development applications across the full spectrum of transcatheter valves."

Admedus recently beats revenue forecasts for financial year 2017, after delivering a full year sales increase of 58% to $22.3 million.

READ NOW: Admedus beats revenue forecasts

View full AHZ profile View Profile

Admedus Ltd Timeline

November 01 2018

Related Articles

man and woman working in a lab
October 11 2018
There were no adverse safety findings and excellent drug-like properties were confirmed.
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
consumer health segment overview
The company sells clinically validated anti-ageing products for hair, skin and body.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use